

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GERSHON) Confirmation No.: 5879
Application No.: 10/561,323) Group Art Unit: 1617
Filing Date: December 19, 2005) Examiner: Paul E. Zarek
For: MICROBICIDAL, PROPHYLACTIC) **INFORMATION DISCLOSURE**
AND THERAPEUTIC EFFECT OF) **STATEMENT**
CTC-96 ON PAPILLOMA VIRUSES) Docket No.: JG-RP-5170PCT-US/ZR05.012
PTO Customer Number 28062
Buckley, Maschoff & Talwalkar LLC
50 Locust Avenue
New Canaan, CT 06840

Mail Stop Amendment (via EFS)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.97(b);
(within 3 months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; or before the mailing of a first Office action after the filing a Request for Continued Examination under § 1.114; whichever occurs last)
- ☒ under 37 CFR 1.97(c) together with either a:
- ☐ Statement under 37 CFR 1.97(c)(1): That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, or
- ☐ Statement under 37 CFR 1.97(c)(2): That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement, or

- ☒ \$180.00 fee under 37 CFR 17(p); or
(after 37 CFR 1.97(b) time period, but before final action or notice of allowance,
whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with a:
- ☐ Statement under 37 CFR 1.97(e)(1): That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement,
 - ☐ Statement under 37 CFR 1.97(e)(2): That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement, or
 - ☐ Petition under 37 CFR 1.97(d)(2)(ii), and
 - ☐ \$_ petition fee under 37 CFR 17(i).
(after 37 CFR 1.97(c) time period, but before payment of issue fee)

Applicant submits herewith patents, publications or other information of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a thorough search has been made, an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. Nor shall the filing of this information disclosure statement be construed as an admission against interest in any manner.

This Information Disclosure Statement is filed in accordance with 37 CFR §§1.56, 1.97 and 1.98. The items listed on the accompanying Form PTO/SB/08a may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items listed on the enclosed copy of Form PTO/SB/08a and to independently ascertain their teaching.

The following References listed herein are as follows:

- (1) Cates, W., Jr. Estimates of the Incidence and Prevalence of Sexually Transmitted Diseases in the United States. American Social Health Association Panel. *Sex Transm Dis.* **1999**, 26, S2-S7.
- (2) Takeuchi, T.; Bottcher, A.; Quezada, C. M.; Meade, T. J.; Gray, H. B. Inhibition of Thermolysin and Human Alpha-Thrombin by Cobalt(III) Schiff BaSe Complexes. *Bioorg. Med. Chem.* **1999**, 7, 815-819.
- (3) Schwartz, J. A.; Lium, E. K.; Silverstein, S. J. Herpes Simplex Virus Type 1 Entry Is Inhibited by the Cobalt Chelate Complex CTC-96. *J. Virol.* **2001**, 75, 4117-4128.
- (4) Strike, D. G.; Bonnez, W.; Rose, R. C.; Reichman, R. C. Expression in Escherichia Coli of Seven DNA Fragments Comprising the Complete L1 and L2 Open Reading Frames of Human Papillomavirus Type 6b and Localization of the 'Common Antigen' Region. *J. Gen. Virol* **1989**, 70, 543-555.
- (5) Bonnez, W.; Darrin, C.; Simpson, V. Virucidal Effect of CTC-96 Against Human Papilloma Virus (HPV) Type 11. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). DOE 1999.

Ref Type: Abstract

- (6) Bonnez, W.; Simpson, V.; Darrin, C. Evaluation OF THE ACTIVITY OF TOPICAL CTC-96 (CTC-96) (REDOX CORP) ON HPV-11-INDUCED HUMAN XENOGRAFTS IN THE SEVERE COMBINED IMMUNODEFICIENCY SCID) MOUSE MODEL. Proceedings of the 18th Papilloma Conference (7/2000). 2000. Ref Type: Abstract
- (7) David Gershon, "Microbicidal, Prophylactic and Therapeutic Effect of CTC-96 on Papilloma Viruses", Provisional Application No. 60/480,206, filed June 20, 2003, 19 pages.

Respectfully submitted,

August 31, 2009
Date

/Jules E. Goldberg/
Jules E. Goldberg, Registration No. 24,408
Buckley, Maschoff & Talwalkar LLC
50 Locust Avenue, New Canaan, CT 06840
203-716-2282